Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ran Zuo
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Soochow University,
Tianjin Medical University
ORCID:
0000-0003-2274-1080
Observed ORCIDs:
0000-0003-2274-1080,
0009-0003-0483-6737
OpenAlex ID:
A5036275489
PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
2024
·
Na Li
, Ran Zuo
, et al.
·
Cell Death and Disease
·
58
PDF
The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma
2023
·
Yuchao He
, Linlin Zhan
, et al.
·
Advanced Science
·
43
PDF
A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors
2021
·
Gengwei Huo
, Yali Wang
, et al.
·
Frontiers in Oncology
·
39
PDF
Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
2023
·
Jinfang Cui
, Yuchao He
, et al.
·
International Journal of Biological Sciences
·
35
PDF
The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma
2023
·
Ran Zuo
, Fuyi Zhu
, et al.
·
Thoracic Cancer
·
30
PDF
TWF1 induces autophagy and accelerates malignant phenotype in lung adenocarcinoma via inhibiting the cAMP signaling pathway
2023
·
Yu Wang
, Ran Zuo
, et al.
·
The FASEB Journal
·
15
PDF
CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma
2024
·
Ping Yue
, Yuchao He
, et al.
·
Cancer Gene Therapy
·
12
High incidence and reversible bradycardia events following alectinib initiation
2022
·
Dongqi Yuan
, Fuyi Zhu
, et al.
·
Thoracic Cancer
·
11
PDF
Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
2020
·
Ran Zuo
, Cuicui Zhang
, et al.
·
Thoracic Cancer
·
11
PDF
5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma
2025
·
Yuanying Feng
, Yuchao He
, et al.
·
EMBO Molecular Medicine
·
10
PDF
MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
2021
·
Yan-Ling Chen
, Zi-Mu Zhang
, et al.
·
Oncology Letters
·
10
PDF
Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
2021
·
Geng-wei Huo
, Ran Zuo
, et al.
·
Open Medicine
·
10
PDF
[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].
2018
·
Yudong Su
, Zhaoting Meng
, et al.
·
PubMed Central
·
9
PDF
STK11/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy
2025
·
Ziyi Dong
, Ran Zuo
, et al.
·
Translational Lung Cancer Research
·
7
OVOL2 induces autophagy-mediated epithelial-mesenchymal transition by the ERK1/2 MAPK signaling in lung adenocarcinoma
2024
·
Yali Wang
, Lin Shi
, et al.
·
iScience
·
6
Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S : A case report and literature review
2020
·
Cuicui Zhang
, Li Lin
, et al.
·
Thoracic Cancer
·
6
Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report
2022
·
Zhaoting Meng
, Cuicui Zhang
, et al.
·
Anti-Cancer Drugs
·
5
DNAJC24 acts directly with PCNA and promotes malignant progression of LUAD by activating phosphorylation of AKT
2024
·
Dongming Liu
, Ran Zuo
, et al.
·
The FASEB Journal
·
4
The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis
2021
·
Geng-Wei Huo
, Fu-Yi Zhu
, et al.
·
Translational Cancer Research
·
4
PDF
Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy
2026
·
Huiya Wang
, Haiyan Sun
, et al.
·
Frontiers in Immunology
·
3
PDF
Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy
2025
·
Yuan Gao
, Yuchao He
, et al.
·
Cell Reports Medicine
·
2
NCAM1 potentiates small cell lung cancer stemness and resistance to NK cell-mediated cytotoxicity
2026
·
Jing Qi
, Haiyan Sun
, et al.
·
Cell Death and Disease
PDF
cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment
2026
·
Ran Zuo
, Yuchao He
, et al.
·
Communications Biology
PDF
Evaluation of the efficacy and safety of anlotinib in postoperative non-pCR non-small cell lung cancer.
2025
·
Jie Xu
, Ran Zuo
, et al.
·
Journal of Clinical Oncology
PDF
Individualized Prognostic Score for Lung Adenocarcinoma Based on Immune Status
2022
·
Peng Chen
, Mihray Abdurazik
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
25
Citation count:
330
H-index:
10
I10-index:
12
Year
Topic
Type